VTYX Key Statistics, Chart & Performance
The current stock price of VTYX is 10.34 USD. In the past month the price increased by 54.5%. In the past year, price increased by 271.27%.
VTYX Latest News, Press Relases and Analysis
VTYX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50 | 1.04T | ||
| JNJ | JOHNSON & JOHNSON | 19.99 | 499.75B | ||
| MRK | MERCK & CO. INC. | 11.86 | 260.99B | ||
| PFE | PFIZER INC | 8.01 | 145.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.42 | 99.05B | ||
| ZTS | ZOETIS INC | 20.29 | 57.02B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.61 | 23.03B | ||
| VTRS | VIATRIS INC | 4.54 | 12.33B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.13 | 11.51B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.74 | 8.49B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.57B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.23B |
Related stock screener links
About VTYX
Company Profile
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 81 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Company Info
VENTYX BIOSCIENCES INC
12790 El Camino Real, Suite 200
San Diego CALIFORNIA US
Employees: 81
Phone: 18589452393
VENTYX BIOSCIENCES INC / VTYX FAQ
Can you describe the business of VENTYX BIOSCIENCES INC?
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 81 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Can you provide the latest stock price for VENTYX BIOSCIENCES INC?
The current stock price of VTYX is 10.34 USD. The price increased by 3.92% in the last trading session.
What is the dividend status of VENTYX BIOSCIENCES INC?
VTYX does not pay a dividend.
What is the ChartMill rating of VENTYX BIOSCIENCES INC stock?
VTYX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for VENTYX BIOSCIENCES INC?
VENTYX BIOSCIENCES INC (VTYX) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy VTYX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VTYX.
Can you provide the ownership details for VTYX stock?
You can find the ownership structure of VENTYX BIOSCIENCES INC (VTYX) on the Ownership tab.
VTYX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VTYX. When comparing the yearly performance of all stocks, VTYX is one of the better performing stocks in the market, outperforming 99.43% of all stocks.
VTYX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VTYX. No worries on liquidiy or solvency for VTYX as it has an excellent financial health rating, but there are worries on the profitability.
VTYX Financial Highlights
Over the last trailing twelve months VTYX reported a non-GAAP Earnings per Share(EPS) of -1.5. The EPS increased by 36.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.41% | ||
| ROE | -55.71% | ||
| Debt/Equity | 0 |
VTYX Forecast & Estimates
15 analysts have analysed VTYX and the average price target is 13.99 USD. This implies a price increase of 35.29% is expected in the next year compared to the current price of 10.34.